Ultra-long-acting biodegradable polymeric solid implants for HIV treatment maintenance
Thursday, July 17, 2025
11:05 AM – 11:16 AM EDT
Introduction: Ultra-long-acting (ULA) formulations that can deliver antiretroviral drugs (ARVs) for six months or longer can mitigate the heavy pill burden and significantly enhance adherence to HIV treatment. Thus, we propose to develop ULA biodegradable polymeric solid implants (PSIs) that can deliver Cabotegravir (CAB) and Rilpivirine (RPV) at target therapeutic concentrations. We have investigated the feasibility to fabricate PSIs that can accommodate high drug loading and achieve zero order release kinetics of CAB and RPV at target release rates in vitro and in vivo in mice over six months.
Learning Objectives:
At the completion of this activity, participants will know
Formulation of CAB and RPV as ULA PSIs with individual drug concentrations ≥ 600 mg/g.
To assess the in-vitro and in vivo pharmacokinetics and safety of the proposed CAB and RPV PSIs.
